U.S. COVID-19 Vaccine Product Information

alert icon

CDC and FDA have recommended a pause in the use of the Janssen (Johnson & Johnson) COVID-19 vaccine in the United States out of an abundance of caution, effective Tuesday, April 13. Of the 6.8 million Janssen COVID-19 vaccine doses administered in the United States to date, six cases of a type of blood clot called “cerebral venous sinus thrombosis” (CVST) were seen in combination with low levels of blood platelets (thrombocytopenia). CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14, to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.

If you are a COVID-19 Vaccination Provider with Janssen (Johnson & Johnson) vaccine:

  1. Mark any Janssen/J&J vaccine in your inventory “Do not use. Awaiting guidance.”
  2. Continue to store the vaccine in the refrigerator between 2°C and 8°C (36°F and 46°F).
  3. Follow vaccine storage practices and continue to monitor and document storage unit temperatures.

Find a suite of information and materials that are needed for each specific COVID-19 vaccine that cover administration, storage and handling, safety, and reporting.

Page last reviewed: March 2, 2021